A new #CCTG clinical trial, ALC.8, is open for people with newly diagnosed, untreated high-risk acute myeloid leukemia (#AML). As part of #myeloMATCH, the study is comparing four treatment combinations with standard therapy. #ClinicalTrials #CancerResearch
buff.ly/BVE1zY5
September 2, 2026 at 11:30 AM
A new #CCTG clinical trial, ALC.8, is open for people with newly diagnosed, untreated high-risk acute myeloid leukemia (#AML). As part of #myeloMATCH, the study is comparing four treatment combinations with standard therapy. #ClinicalTrials #CancerResearch
buff.ly/BVE1zY5
#LegacyContent: Analytical performance of the NCI-myeloMATCH assay – a rapid turnaround genomic profiling assay for myeloid disorders.
Free in the #OpenArchive: www.jmdjournal.org/article/S152...
Free in the #OpenArchive: www.jmdjournal.org/article/S152...
Analytical Performance of the NCI-myeloMATCH Assay
myeloMATCH is a National Cancer Institute (NCI) precision medicine clinical trial
initiative to evaluate treatments for acute myeloid leukemia and myelodysplastic syndrome
based on a leukemia’s diagno...
www.jmdjournal.org
August 25, 2026 at 9:30 PM
#LegacyContent: Analytical performance of the NCI-myeloMATCH assay – a rapid turnaround genomic profiling assay for myeloid disorders.
Free in the #OpenArchive: www.jmdjournal.org/article/S152...
Free in the #OpenArchive: www.jmdjournal.org/article/S152...
ICYMI: NCI’s myeloMATCH pushes the envelope in myeloid leukemia care
sohoinsider.com/leukemia/nci...
sohoinsider.com/leukemia/nci...
NCI’s myeloMATCH pushes the envelope in myeloid leukemia care
A new National Cancer Institute (NCI) initiative seeks to redefine the standard for personalized cancer care in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Known as myeloMATCH—(M...
sohoinsider.com
March 4, 2025 at 1:48 AM
ICYMI: NCI’s myeloMATCH pushes the envelope in myeloid leukemia care
sohoinsider.com/leukemia/nci...
sohoinsider.com/leukemia/nci...
NCI approved clinical research studies in metastatic colorectal cancer, pediatric high grade glioma, ALL, head and neck chemo, breast cancer, sub-studies of MyeloMATCH and Lung-MAP, and an education/mentorship study within the NCORP network.
https://cancerletter.com/nci-trials/20250509_12/
https://cancerletter.com/nci-trials/20250509_12/
NCI Trials for May 2025 - The Cancer Letter
The National Cancer Institute approved the following clinical research studies last month. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe
cancerletter.com
May 12, 2025 at 1:00 AM
NCI approved clinical research studies in metastatic colorectal cancer, pediatric high grade glioma, ALL, head and neck chemo, breast cancer, sub-studies of MyeloMATCH and Lung-MAP, and an education/mentorship study within the NCORP network.
https://cancerletter.com/nci-trials/20250509_12/
https://cancerletter.com/nci-trials/20250509_12/
Analytical performance of the NCI-myeloMATCH assay – a rapid turnaround genomic profiling assay for myeloid disorders. Authors from @fredhutch.bsky.social.
Full text: https://www.jmdjournal.org/article/S1525-1578(25)00116-3/fulltext
Full text: https://www.jmdjournal.org/article/S1525-1578(25)00116-3/fulltext
August 5, 2025 at 1:28 PM
Analytical performance of the NCI-myeloMATCH assay – a rapid turnaround genomic profiling assay for myeloid disorders. Authors from @fredhutch.bsky.social.
Full text: https://www.jmdjournal.org/article/S1525-1578(25)00116-3/fulltext
Full text: https://www.jmdjournal.org/article/S1525-1578(25)00116-3/fulltext
Fred Hutch's Min Fang presenting work at #ASH25 showing chromosome genomic array testing (CGAT) improves diagnostic yield in patients with #AML and #MDS and has the potential for better risk stratification - an NCI myeloMATCH and @swog.org report. ashpublications.org/blood/articl...
December 8, 2025 at 12:23 AM
Fred Hutch's Min Fang presenting work at #ASH25 showing chromosome genomic array testing (CGAT) improves diagnostic yield in patients with #AML and #MDS and has the potential for better risk stratification - an NCI myeloMATCH and @swog.org report. ashpublications.org/blood/articl...
Fred Hutch's Xiaoyu Qu presenting work at #ASH25 on improving karyotype success for myeloMATCH. Enhanced workflows boosted karyotype yield in AML samples, ensuring more patients receive accurate cytogenetic data for precision trial enrollment. ashpublications.org/blood/articl...
December 8, 2025 at 12:21 AM
Fred Hutch's Xiaoyu Qu presenting work at #ASH25 on improving karyotype success for myeloMATCH. Enhanced workflows boosted karyotype yield in AML samples, ensuring more patients receive accurate cytogenetic data for precision trial enrollment. ashpublications.org/blood/articl...
A new #myeloMATCH clinical trial, #CCTG ALC10 has opened in Canada! Exploring a new treatment option for older adults with acute myeloid leukemia #AML who may not be able to tolerate intensive chemotherapy.
buff.ly/ABTpHbj
#Hematology #ClinicalTrials #BCCancer @swog.org
buff.ly/ABTpHbj
#Hematology #ClinicalTrials #BCCancer @swog.org
June 11, 2026 at 11:30 AM
A new #myeloMATCH clinical trial, #CCTG ALC10 has opened in Canada! Exploring a new treatment option for older adults with acute myeloid leukemia #AML who may not be able to tolerate intensive chemotherapy.
buff.ly/ABTpHbj
#Hematology #ClinicalTrials #BCCancer @swog.org
buff.ly/ABTpHbj
#Hematology #ClinicalTrials #BCCancer @swog.org
The @theNCI #MyeloMATCH precision medicine trial for #AML or #MDS has some initial results that are being presented in an oral presentation and 5 posters at the #ASH25 meeting this weekend! Find out more here > buff.ly/6HaGwyz
@SWOG
@eaonc
@ALLIANCE_org
#NCORP
@SWOG
@eaonc
@ALLIANCE_org
#NCORP
December 5, 2025 at 7:45 PM
The @theNCI #MyeloMATCH precision medicine trial for #AML or #MDS has some initial results that are being presented in an oral presentation and 5 posters at the #ASH25 meeting this weekend! Find out more here > buff.ly/6HaGwyz
@SWOG
@eaonc
@ALLIANCE_org
#NCORP
@SWOG
@eaonc
@ALLIANCE_org
#NCORP
#CCTG trial spotlight for #LeukemiaAwarenessMonth & #ChildhoodCancerAwarenessMonth: The ALC6 study is testing if adding another drug to standard treatment improves outcomes for young adults with newly diagnosed B-cell acute lymphoblastic leukemia.
#myeloMATCH
Trial Info -> buff.ly/TZ0YRC0
#myeloMATCH
Trial Info -> buff.ly/TZ0YRC0
September 29, 2025 at 11:45 AM
#CCTG trial spotlight for #LeukemiaAwarenessMonth & #ChildhoodCancerAwarenessMonth: The ALC6 study is testing if adding another drug to standard treatment improves outcomes for young adults with newly diagnosed B-cell acute lymphoblastic leukemia.
#myeloMATCH
Trial Info -> buff.ly/TZ0YRC0
#myeloMATCH
Trial Info -> buff.ly/TZ0YRC0
#CCTG Trial Highlight for #LeukemiaAwarenessMonth : ALC8 is testing four innovative treatment combinations for newly diagnosed high-risk acute #myeloid #leukemia to find better first-line options for patients.
#myeloMATCH #SolvingCancerTogether
Trial info -> buff.ly/NLWIgT7
#myeloMATCH #SolvingCancerTogether
Trial info -> buff.ly/NLWIgT7
September 22, 2025 at 8:12 PM
#CCTG Trial Highlight for #LeukemiaAwarenessMonth : ALC8 is testing four innovative treatment combinations for newly diagnosed high-risk acute #myeloid #leukemia to find better first-line options for patients.
#myeloMATCH #SolvingCancerTogether
Trial info -> buff.ly/NLWIgT7
#myeloMATCH #SolvingCancerTogether
Trial info -> buff.ly/NLWIgT7
#CCTG has presented the Phase III Program Team Award for an intergroup led trial to the ALC.7 team from Arthur J.E. Child Comprehensive Cancer Centre for their performance on this #myeloMATCH protocol. #CCTG2025
April 27, 2025 at 8:01 PM
#CCTG has presented the Phase III Program Team Award for an intergroup led trial to the ALC.7 team from Arthur J.E. Child Comprehensive Cancer Centre for their performance on this #myeloMATCH protocol. #CCTG2025
The #CCTG ALC8 trial has opened, testing the effects of novel therapeutics for newly diagnosed, untreated acute myeloid leukemia #AML patients. This trial is part of the #myeloMATCH precision medicine protocol for #AML #MDS patients. #SolvingCancerTogether
https://buff.ly/419yN3S
https://buff.ly/419yN3S
February 12, 2025 at 4:07 PM
The #CCTG ALC8 trial has opened, testing the effects of novel therapeutics for newly diagnosed, untreated acute myeloid leukemia #AML patients. This trial is part of the #myeloMATCH precision medicine protocol for #AML #MDS patients. #SolvingCancerTogether
https://buff.ly/419yN3S
https://buff.ly/419yN3S
#APTO Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
#news #investing #stocks
https://www.stocktitan.net/news/APTO/aptose-signs-crada-with-nci-to-develop-tuspetinib-for-aml-and-mds-in-tj1xgx9x1rpp.html
#news #investing #stocks
https://www.stocktitan.net/news/APTO/aptose-signs-crada-with-nci-to-develop-tuspetinib-for-aml-and-mds-in-tj1xgx9x1rpp.html
Aptose Partners with NCI to Advance Tuspetinib Cancer Treatment in Clinical Trials | APTO Stock News
Aptose Biosciences teams with National Cancer Institute to develop tuspetinib for AML/MDS treatment through myeloMATCH trials, plus launches Phase 1/2 TUSCANY study.
www.stocktitan.net
December 3, 2024 at 12:30 PM
#APTO Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
#news #investing #stocks
https://www.stocktitan.net/news/APTO/aptose-signs-crada-with-nci-to-develop-tuspetinib-for-aml-and-mds-in-tj1xgx9x1rpp.html
#news #investing #stocks
https://www.stocktitan.net/news/APTO/aptose-signs-crada-with-nci-to-develop-tuspetinib-for-aml-and-mds-in-tj1xgx9x1rpp.html
excited to be able to highlight our Myelomatch study for IDH2-mutated MDS at the ongoing Alliance meeting!
November 7, 2025 at 6:57 PM
excited to be able to highlight our Myelomatch study for IDH2-mutated MDS at the ongoing Alliance meeting!
Very excited to share that that the Myelomatch study I am leading is open to accrual! We are investigating ASTX727 +/- enasidenib in higher-risk IDH2m MDS
clinicaltrials.gov/study/NCT065...
clinicaltrials.gov/study/NCT065...
April 10, 2025 at 8:03 PM
Very excited to share that that the Myelomatch study I am leading is open to accrual! We are investigating ASTX727 +/- enasidenib in higher-risk IDH2m MDS
clinicaltrials.gov/study/NCT065...
clinicaltrials.gov/study/NCT065...
Attending #ASH25 this weekend? Don't miss the initial results from the myeloMATCH #PrecisionMedicine trial. More info on these exciting updates can be found here: dctd.cancer.gov/about/news-e...
MyeloMATCH Presentations at ASH 2025
NCI's presentations on MyeloMATCH at the 2025 American Society of Hematology Annual Meeting
dctd.cancer.gov
December 5, 2025 at 7:14 PM
Attending #ASH25 this weekend? Don't miss the initial results from the myeloMATCH #PrecisionMedicine trial. More info on these exciting updates can be found here: dctd.cancer.gov/about/news-e...
The NCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more:
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
December 1, 2025 at 1:46 PM
The NCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more:
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
#myeloMATCH is the NCI’s #PrecisionMedicine trial in #myeloid cancers. Substudy MM1OA-S03
enrolls patients who are age 60+ or unfit for chemo and have newly diagnosed AML with an
IDH2 gene mutation (~15% of pts).
swog.org/clinical-trials/MM1OA-S03 #leusm #leukemia @urochester.bsky.social
enrolls patients who are age 60+ or unfit for chemo and have newly diagnosed AML with an
IDH2 gene mutation (~15% of pts).
swog.org/clinical-trials/MM1OA-S03 #leusm #leukemia @urochester.bsky.social
June 11, 2025 at 7:55 PM
#myeloMATCH is the NCI’s #PrecisionMedicine trial in #myeloid cancers. Substudy MM1OA-S03
enrolls patients who are age 60+ or unfit for chemo and have newly diagnosed AML with an
IDH2 gene mutation (~15% of pts).
swog.org/clinical-trials/MM1OA-S03 #leusm #leukemia @urochester.bsky.social
enrolls patients who are age 60+ or unfit for chemo and have newly diagnosed AML with an
IDH2 gene mutation (~15% of pts).
swog.org/clinical-trials/MM1OA-S03 #leusm #leukemia @urochester.bsky.social
#myeloMATCH sub-study MM1OA-S03 is open!
Patients registered to MYELOMATCH screening protocol who are 60+ or unfit for chemo and have AML w an IDH2 gene mutation may be assigned. Randomized to venetoclax + ASTX727 w/wo enasidenib.
swog.org/clinical-trials/MM1OA-S03 @beatalleukemia.bsky.social
Patients registered to MYELOMATCH screening protocol who are 60+ or unfit for chemo and have AML w an IDH2 gene mutation may be assigned. Randomized to venetoclax + ASTX727 w/wo enasidenib.
swog.org/clinical-trials/MM1OA-S03 @beatalleukemia.bsky.social
April 2, 2025 at 3:44 PM
#myeloMATCH sub-study MM1OA-S03 is open!
Patients registered to MYELOMATCH screening protocol who are 60+ or unfit for chemo and have AML w an IDH2 gene mutation may be assigned. Randomized to venetoclax + ASTX727 w/wo enasidenib.
swog.org/clinical-trials/MM1OA-S03 @beatalleukemia.bsky.social
Patients registered to MYELOMATCH screening protocol who are 60+ or unfit for chemo and have AML w an IDH2 gene mutation may be assigned. Randomized to venetoclax + ASTX727 w/wo enasidenib.
swog.org/clinical-trials/MM1OA-S03 @beatalleukemia.bsky.social
#myeloMATCH substudies treat patients with #AML or #MDS sequentially from diagnosis thru all treatment stages. After each treatment, patients are rescreened for assignment to a substudy in another tier. #NCI @eaonc.bsky.social @swog.org
swog.org/myeloMATCH-overview
swog.org/myeloMATCH-overview
March 31, 2025 at 8:49 PM
#myeloMATCH substudies treat patients with #AML or #MDS sequentially from diagnosis thru all treatment stages. After each treatment, patients are rescreened for assignment to a substudy in another tier. #NCI @eaonc.bsky.social @swog.org
swog.org/myeloMATCH-overview
swog.org/myeloMATCH-overview
#myeloMATCH MM1YA-S01 is enrolling adults ages 18-59 with newly diagnosed high-risk #AML.
Randomized 5-arm comparison of induction therapies. Primary endpoint: MRD-negative complete remission rate. swog.org/clinical-tri...
Co-PI: Tara Lin, MD #leusm #AMLsm #leukemia
Randomized 5-arm comparison of induction therapies. Primary endpoint: MRD-negative complete remission rate. swog.org/clinical-tri...
Co-PI: Tara Lin, MD #leusm #AMLsm #leukemia
January 8, 2025 at 5:43 PM
#myeloMATCH MM1YA-S01 is enrolling adults ages 18-59 with newly diagnosed high-risk #AML.
Randomized 5-arm comparison of induction therapies. Primary endpoint: MRD-negative complete remission rate. swog.org/clinical-tri...
Co-PI: Tara Lin, MD #leusm #AMLsm #leukemia
Randomized 5-arm comparison of induction therapies. Primary endpoint: MRD-negative complete remission rate. swog.org/clinical-tri...
Co-PI: Tara Lin, MD #leusm #AMLsm #leukemia
Dr. Harry Erba interviewed by Society of Hematologic Oncology news on #myeloMATCH trial in AML & MDS: "It’s about creating a model for how we can use science, technology, and collaboration to revolutionize cancer care." @eaonc.bsky.social @dukemedschool.bsky.social
sohoinsider.com/leukemia/nci...
sohoinsider.com/leukemia/nci...
NCI’s myeloMATCH precision medicine initiative pushes the envelope in myeloid leukemia care
A new National Cancer Institute (NCI) initiative seeks to redefine the standard for personalized cancer care in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Known as MyeloMATCH— (M...
sohoinsider.com
January 3, 2025 at 3:15 PM
Dr. Harry Erba interviewed by Society of Hematologic Oncology news on #myeloMATCH trial in AML & MDS: "It’s about creating a model for how we can use science, technology, and collaboration to revolutionize cancer care." @eaonc.bsky.social @dukemedschool.bsky.social
sohoinsider.com/leukemia/nci...
sohoinsider.com/leukemia/nci...